Sirnaomics Ltd. (HK:2257)
:2257
Top Page
Sirnaomics Ltd.
(2257)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$8.00
▲(0.00% Upside)
Action:ReiteratedDate:01/06/26
The score is primarily weighed down by weak financial performance (ongoing losses, negative equity, and negative free cash flow). Technical indicators are mixed and provide only modest support, while valuation is constrained by a loss-making profile and no dividend yield data.
Positive Factors
Proprietary RNAi platform & partnerships
A proprietary siRNA design and optimization platform plus academic and pharma collaborations provide durable R&D and commercialization advantages. These assets support sustained pipeline development, licensing opportunities, and reduced time-to-market vs. newcomers, bolstering long-term competitivenes.
Negative Factors
Negative stockholders' equity
Negative equity is a structural solvency concern that limits financial flexibility and access to capital. Over months this raises default and covenant risk, can deter partners or lenders, and may force dilutive financing or asset sales to sustain operations if cash burn persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary RNAi platform & partnerships
A proprietary siRNA design and optimization platform plus academic and pharma collaborations provide durable R&D and commercialization advantages. These assets support sustained pipeline development, licensing opportunities, and reduced time-to-market vs. newcomers, bolstering long-term competitivenes.
Read all positive factors
Sirnaomics Ltd. (2257) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$717.58M
Dividend YieldN/A
Average Volume (3M)442.62K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue GrowthN/A
EPS Growth83.89%
CountryHK
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding109,721,535
10 Day Avg. Volume408,789
30 Day Avg. Volume442,620
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-20.53
Price to Sales (P/S)19.40
P/FCF Ratio-1.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Sirnaomics Ltd. Business Overview & Revenue Model
Company Description
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates i...
How the Company Makes Money
Sirnaomics generates revenue primarily through a combination of product sales, research grants, and collaborations with other pharmaceutical companies. The company's revenue model is driven by the successful development and commercialization of it...
Sirnaomics Ltd. Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 949.00K | 1.78M | 397.00K | 705.00K | 0.00 | 0.00 |
| Gross Profit | 370.00K | 1.20M | 397.00K | 705.00K | -12.67M | 0.00 |
| EBITDA | -15.48M | -31.12M | -72.36M | -89.02M | -1.66B | -19.27M |
| Net Income | -14.02M | -51.38M | -78.69M | -88.30M | -1.66B | -43.77M |
Balance Sheet | ||||||
| Total Assets | 21.30M | 28.33M | 75.79M | 163.93M | 240.65M | 110.18M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 11.77M | 43.93M | 105.23M | 211.99M | 103.12M |
| Total Debt | 7.21M | 8.06M | 8.85M | 10.76M | 7.04M | 91.87M |
| Total Liabilities | 40.40M | 44.33M | 51.33M | 52.37M | 30.36M | 204.36M |
| Stockholders Equity | -5.12M | -1.68M | 40.20M | 122.01M | 211.62M | -94.43M |
Cash Flow | ||||||
| Free Cash Flow | -9.26M | -19.84M | -72.03M | -107.54M | -62.85M | -21.15M |
| Operating Cash Flow | -9.26M | -19.73M | -70.29M | -88.71M | -56.97M | -19.00M |
| Investing Cash Flow | 1.94M | 2.14M | -5.35M | -32.61M | -6.04M | 8.39M |
| Financing Cash Flow | 6.53M | 5.82M | -5.61M | 15.89M | 170.96M | 100.37M |
Sirnaomics Ltd. Technical Analysis
Neutral
8.00
Price Trends
7.00
Negative
7.68
Negative
8.94
Negative
Market Momentum
-0.22
Negative
52.49
Neutral
74.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2257, the sentiment is Neutral. The current price of 8 is above the 20-day moving average (MA) of 6.16, above the 50-day MA of 7.00, and below the 200-day MA of 8.94, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 52.49 is Neutral, neither overbought nor oversold. The STOCH value of 74.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2257.
Sirnaomics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
52 Neutral | HK$3.70B | -13.26 | 11.40% | ― | 79.98% | -3.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$717.58M | -2.18 | 191.92% | ― | ― | 83.89% | |
43 Neutral | HK$1.25B | -2.47 | -27.44% | ― | -57.84% | 24.58% | |
42 Neutral | HK$13.59B | -15.44 | -64.19% | ― | -55.64% | -158.67% |
* Healthcare Sector Average
HK:2257
Sirnaomics Ltd.
6.54
3.49
114.43%
HK:1875
TOT BIOPHARM International Co. Ltd.
5.00
3.40
212.50%
HK:2197
Clover Biopharmaceuticals Ltd.
2.85
2.65
1325.00%
HK:2616
CStone Pharmaceuticals
9.35
7.13
321.17%
HK:3681
SinoMab Bioscience Ltd.
1.76
0.58
49.15%
HK:6628
Transcenta Holding Limited
2.82
1.68
147.37%
Sirnaomics Ltd. Corporate Events
Sirnaomics Completes Phase I Trial of Cancer Drug STP707 and Files Clinical Report with FDA
Dec 22, 2025
Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a Phase I clinical trial of its investigational cancer drug STP707 in adults with advanced, metastatic or inoperable solid tumors that were no longer responding to st...
Sirnaomics Chairman Increases Stake, Signaling Confidence in Growth
Dec 8, 2025
Sirnaomics Ltd. announced that Dr. Poon Hung Fai, the company’s chairman and executive director, has increased his shareholding by purchasing 100,000 ordinary shares at an average price of HK$6.83 per share. This move reflects Dr. Poon’...
Sirnaomics Ltd. Completes Partial Share Subscription to Boost Drug Development
Dec 7, 2025
Sirnaomics Ltd. announced the partial completion of a subscription agreement, resulting in the issuance of 1,003,700 new shares to Subscriber B at HK$12.00 per share. The termination of the remaining shares in the agreement was mutually agreed upo...
Sirnaomics Ltd. Announces Board of Directors and Committee Roles
Dec 1, 2025
Sirnaomics Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.